Literature DB >> 6293813

In vitro activity of ceftazidime, cefotaxime and piperacillin against multi-resistant gram-negative bacteria tested with a modified agar dilution method.

J A Hoogkamp-Korstanje, C A Meijer.   

Abstract

The minimum inhibitory concentrations of ceftazidime, cefotaxime and piperacillin were determined for 870 multi-resistant gram-negative bacterial strains by means of a modified agar dilution technique using dishes with 25 compartments. This technique facilitates the reading of the MICs, reduces the risk of inoculation errors, and eliminates interference of interaction of bacterial strains. Ceftazidime and cefotaxime inhibited 90% of the Enterobacteriaceae strains at concentrations of 3.12 mg/l and 1.56 mg/l respectively. Ceftazidime and piperacillin inhibited 90% of the Pseudomonas aeruginosa strains at concentrations of 6.25 mg/l and 12.5 mg/l respectively. Mucoid Pseudomonas aeruginosa strains were more susceptible to the antibiotics tested, especially piperacillin, than non-mucoid strains.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6293813     DOI: 10.1007/bf02019618

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  11 in total

1.  Behaviour of ceftazidime towards beta-lactamases.

Authors:  R Labia; R Beguin-Billecoq; M Guionie
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

2.  Antibiotic therapy and cystic fibrosis: increased resistance of mucoid Pseudomonas aeruginosa to carbenicillin.

Authors:  J R Govan
Journal:  J Antimicrob Chemother       Date:  1976-06       Impact factor: 5.790

3.  Human metabolism of cefotaxime.

Authors:  D S Reeves; L O White; H A Holt; D Bahari; M J Bywater; R P Bax
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

4.  Cefotaxime in septicaemia including typhoid fever.

Authors:  M W McKendrick; A M Geddes; R Wise; R Bax
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

5.  Pseudomonas aeruginosa infections: persisting problems and current research to find new therapies.

Authors: 
Journal:  Ann Intern Med       Date:  1975-06       Impact factor: 25.391

6.  Activity of ceftazidime against Pseudomonas aeruginosa from bacteraemic and fibrocystic patients.

Authors:  P C Fleming; B Knie
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

7.  The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers.

Authors:  S M Harding; A J Monro; J E Thornton; J Ayrton; M I Hogg
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

8.  Use of ceftazidime in severe Gram-negative infections--a preliminary study.

Authors:  N Clumeck; Y Vanlaethem; B Gordts; N Jaspar; J P Butzler
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

9.  In-vitro comparison of ceftazidime and nine other antimicrobial agents against hospital strains of Gram-negative bacteria.

Authors:  L D Wilkinson; L O Gentry
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

10.  GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

View more
  5 in total

1.  The possible role of quinolones in yersiniosis.

Authors:  J A Hoogkamp-Korstanje
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.

Authors:  J A Hoogkamp-Korstanje
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

3.  In vitro comparison of aminoglycoside activities and their synergistic action with piperacillin.

Authors:  J A Hoogkamp-Korstanje
Journal:  Infection       Date:  1985 Jan-Feb       Impact factor: 3.553

Review 4.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

Review 5.  Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; D M Richards; R N Brogden; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.